Inés Suárez-García1, Paz Sobrino-Vegas2, David Dalmau3, Rafael Rubio4, José Antonio Iribarren5, José Ramón Blanco6, Félix Gutierrez7, Marta Montero Alonso8, Enrique Bernal9, David Vinuesa García10, Julia Del Amo2. 1. Infectious Diseases Unit, Department of Internal Medicine, Hospital Universitario Infanta Sofía, Madrid, Spain. 2. Centro Nacional de Epidemiología, Instituto de Salud Carlos III, Madrid, Spain. 3. Hospital Universitari Mutua Terrassa, Terrassa, Spain. 4. Unidad Infección VIH, Hospital Universitario Doce de Octubre, Madrid, Spain. 5. Department of Infectious Diseases, Hospital Universitario Donostia, Gipuzkoa, Spain. 6. Department of Infectious Diseases, Hospital San Pedro-CIBIR, Logroño, Spain. 7. Infectious Diseases Unit, Hospital General de Elche and Universidad Miguel Hernández, Alicante, Spain. 8. Department of Infectious Diseases, Hospital Universitario La Fe, Valencia, Spain. 9. Hospital Reina Sofía, Murcia, Spain. 10. Unidad de Gestion Clínica de Microbiología y Enfermedades Infecciosas, Hospital Clínico San Cecilio, Granada, Spain.
Abstract
AIMS: To compare patients who acquired HIV infection through use of injected drugs (HIV-IDU) with patients who acquired HIV by sexual transmission (HIV-ST) in terms of late presentation (LP), delay in anti-retroviral treatment (ART) initiation, virological and immunological response to ART, mortality and progression to AIDS. DESIGN: Prospective multi-centre cohort study of HIV-infected subjects naive to ART at entry (Cohort of the Spanish HIV Research Network: CoRIS). SETTING: Thirty-one centres from the Spanish public health-care system. PARTICIPANTS: A total of 9355 patients were included (1064 HIV-IDU and 8291 HIV-ST) during 2004-13. MEASUREMENTS: We compared LP (defined as presentation for care with a CD4 cell count < 350/μl and/or AIDS-defining illness), delayed ART initiation (defined as initiating treatment more than 6 months after the date when treatment was indicated by the guidelines, or not initiating treatment at all when it was indicated), virological and immunological response to ART (defined as viral load < 50 HIV-1 RNA copies/ml and a CD4 count increase of at least 100 cells/μl, respectively, after 1 year of treatment), mortality and progression to AIDS in HIV-IDU and HIV-ST. FINDINGS: Compared with HIV-ST, HIV-IDU had higher risk of LP [odds ratio (OR) = 1.76; 95% confidence interval (CI) = 1.41-2.18], delayed ART initiation (OR 1.87; 95% CI = 1.46-2.40) and higher mortality [hazard ratio (HR) = 1.43; 95% CI = 1.03-2.01] and risk of progression to AIDS [subhazard ratio (SHR) = 1.68; 95% CI = 1.29-2.18]. Virological suppression due to ART was lower in HIV-IDU than in patients with HIV-ST only among patients without hepatitis C virus (HCV) infection [adjusted OR (aOR) = 0.59; 95% CI = 0.36-0.95]; among patients with HCV infection, virological suppression due to ART did not show significant differences between HIV-IDU and HIV-ST. There were no significant differences in immunological response after adjusting by HCV (aOR = 0.74; 95% CI = 0.52-1.06). CONCLUSIONS: In Spain, patients who acquire HIV infection through use of injected drugs appear to have a higher risk of late presentation, delayed initiation of anti-retroviral treatment and progression to AIDS and death than patients who acquire HIV by sexual transmission.
AIMS: To compare patients who acquired HIV infection through use of injected drugs (HIV-IDU) with patients who acquired HIV by sexual transmission (HIV-ST) in terms of late presentation (LP), delay in anti-retroviral treatment (ART) initiation, virological and immunological response to ART, mortality and progression to AIDS. DESIGN: Prospective multi-centre cohort study of HIV-infected subjects naive to ART at entry (Cohort of the Spanish HIV Research Network: CoRIS). SETTING: Thirty-one centres from the Spanish public health-care system. PARTICIPANTS: A total of 9355 patients were included (1064 HIV-IDU and 8291 HIV-ST) during 2004-13. MEASUREMENTS: We compared LP (defined as presentation for care with a CD4 cell count < 350/μl and/or AIDS-defining illness), delayed ART initiation (defined as initiating treatment more than 6 months after the date when treatment was indicated by the guidelines, or not initiating treatment at all when it was indicated), virological and immunological response to ART (defined as viral load < 50 HIV-1 RNA copies/ml and a CD4 count increase of at least 100 cells/μl, respectively, after 1 year of treatment), mortality and progression to AIDS in HIV-IDU and HIV-ST. FINDINGS: Compared with HIV-ST, HIV-IDU had higher risk of LP [odds ratio (OR) = 1.76; 95% confidence interval (CI) = 1.41-2.18], delayed ART initiation (OR 1.87; 95% CI = 1.46-2.40) and higher mortality [hazard ratio (HR) = 1.43; 95% CI = 1.03-2.01] and risk of progression to AIDS [subhazard ratio (SHR) = 1.68; 95% CI = 1.29-2.18]. Virological suppression due to ART was lower in HIV-IDU than in patients with HIV-ST only among patients without hepatitis C virus (HCV) infection [adjusted OR (aOR) = 0.59; 95% CI = 0.36-0.95]; among patients with HCV infection, virological suppression due to ART did not show significant differences between HIV-IDU and HIV-ST. There were no significant differences in immunological response after adjusting by HCV (aOR = 0.74; 95% CI = 0.52-1.06). CONCLUSIONS: In Spain, patients who acquire HIV infection through use of injected drugs appear to have a higher risk of late presentation, delayed initiation of anti-retroviral treatment and progression to AIDS and death than patients who acquire HIV by sexual transmission.
Authors: Sophie Patterson; Angela Kaida; Gina Ogilvie; Robert Hogg; Valerie Nicholson; Sabina Dobrer; Thomas Kerr; Jean Shoveller; Julio Montaner; M-J Milloy Journal: Int J Drug Policy Date: 2017-03-28
Authors: Surita Parashar; Alexandra B Collins; Julio S G Montaner; Robert S Hogg; Michael-John Milloy Journal: Curr Opin HIV AIDS Date: 2016-09 Impact factor: 4.283
Authors: T Htun; K W Y Kyaw; T K Aung; J Moe; A A Mon; C L Tun; O Mon; S Satyanarayana; H N Oo Journal: Epidemiol Infect Date: 2019-01 Impact factor: 2.451
Authors: Luz M Medrano; Mónica Gutiérrez-Rivas; Julià Blanco; Marcial García; María A Jiménez-Sousa; Yolanda M Pacheco; Marta Montero; José Antonio Iribarren; Enrique Bernal; Onofre Juan Martínez; José M Benito; Norma Rallón; Salvador Resino Journal: J Transl Med Date: 2018-12-06 Impact factor: 5.531
Authors: Soo Chan Carusone; Adrian Guta; Samantha Robinson; Darrell H Tan; Curtis Cooper; Bill O'Leary; Karen de Prinse; Grant Cobb; Ross Upshur; Carol Strike Journal: Harm Reduct J Date: 2019-02-13